A5013537484- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Lymphoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Platelet Disorders and Treatments
- Multiple Myeloma Research and Treatments
- Blood groups and transfusion
- Biosimilars and Bioanalytical Methods
- Neutropenia and Cancer Infections
- CAR-T cell therapy research
- Hematological disorders and diagnostics
- CNS Lymphoma Diagnosis and Treatment
- Eosinophilic Disorders and Syndromes
- Hemoglobinopathies and Related Disorders
- Blood disorders and treatments
- Safe Handling of Antineoplastic Drugs
- T-cell and Retrovirus Studies
- Silicon Carbide Semiconductor Technologies
- Cancer, Hypoxia, and Metabolism
- Immunodeficiency and Autoimmune Disorders
- Heparin-Induced Thrombocytopenia and Thrombosis
- Synthetic Organic Chemistry Methods
- Galectins and Cancer Biology
- Drug-Induced Adverse Reactions
Hospital Universitario Araba
2013-2024
Osakidetza
2021-2023
Hospital Txagorritxu
2012-2021
Hospital Materno-Infantil
2006
Hospital Universitario Virgen del Rocío
2006
Hospital Universitari Germans Trias i Pujol
2006
Fundación Pethema
2005
Montserrat Volcano Observatory
2005
Purpose The optimal postremission therapy for children with very high-risk (VHR) acute lymphoblastic leukemia (ALL) is not well established. This randomized trial compared three options of therapy: chemotherapy and allogeneic or autologous stem-cell transplantation (SCT). Patients Methods All 106 VHR-ALL patients received induction five drugs followed by intensification cycles chemotherapy. in complete remission (CR) an HLA-identical family donor were assigned to SCT (n = 24) the remaining...
Abstract The use of non‐pegylated liposomal doxorubicin (Myocet ® ) in diffuse large B‐cell lymphoma (DLBCL) has been investigated retrospective and single‐arm prospective studies. This was a phase 2 trial DLBCL patients ≥60 years old with left ventricular ejection fraction (LVEF) ≥55% randomized to standard R‐CHOP or investigational R‐COMP (with Myocet instead conventional doxorubicin). primary end point evaluate the differences subclinical cardiotoxicity, defined as decrease LVEF <55%...
The role of bosutinib as rescue treatment Philadelphia chromosome-positive chronic myeloid leukemia (CML) patients after failing three previous tyrosine kinase inhibitors (TKIs) is currently unknown. We report here the largest series (to our knowledge) treated with in fourth-line, retrospectively reviewing 30 phase, and pretreated imatinib, nilotinib, dasatinib. With a median follow up 11.1 months, probability to either maintain or improve their CCyR response was 56.6% (17/30) 11 (36.7%)...
Diagnosis and management of primary immune thrombocytopenia (ITP) have changed dramatically in the last decade. The aim study was to obtain information about opinion Spanish ITP Group (GEPTI) members regarding best clinical practices for diagnosis adult patients with ITP.A two-round Delphi method carried out by sending 129 experts a 90-item questionnaire developed 11 specialists, 4-point Likert scale ("never," "sometimes," "frequently," "always") assessment responses.Forty participated...
A 64-year-old man presented with a persistent cough. His past medical history included COVID-19 pneumonia one month previously. On admission, full blood count showed haemoglobin concentration of 120 g/l, platelet 98 × 109/l and leukocyte 44 109/l. peripheral film 80% atypical lymphoid cells. Many the abnormal cells had deeply basophilic cytoplasm markedly irregular nuclear contour producing petal-shaped nucleus, mimicking flower adult T-cell leukaemia/lymphoma (ATLL) (all images;...
To assess the incremental cost-utility ratio (ICUR) of gemtuzumab ozogamicin (GO) + standard care (SOC) vs SOC alone for treatment patients with de novo AML from a Spanish Health Service perspective.A cohort state-transition model, 12 health-states, was used to estimate lifetime accumulated cost and benefits in terms quality-adjusted-life-years (QALYs) favourable, intermediate, unknown cytogenetic profiles. Patient profile defined based on ALFA-0701 trial. Therapeutic regimens were by 5...
Primary immune thrombocytopenia (ITP) is an acquired autoimmune disease with highly variable presentation, characteristics, and clinical course. Thrombocytopenia a common complication of many viral infections, including SARS-CoV-2. In addition, both de novo ITP exacerbation after vaccination against SARS-CoV-2 have been reported. Patients infected develop prothrombotic coagulopathy called COVID-19-associated (CAC). hematological disorders secondary to infection, mainly hemolytic anemia...
In this clinical trial, we demonstrate that ultrarapid fast infusion of rituximab (Truxima) in 30 min with oral premedication is feasible and secure for patients, reduce the day-care hospital stays.
Immune thrombocytopenia (ITP) is a common autoimmune hematological disorder. Despite this, diagnosis still challenging due to clinical heterogeneity and the lack of specific diagnostic test. New findings in pathology availability new drugs have led development different guidelines worldwide. In present study, Delphi methodology has been used get consensus on management adult patients with ITP Spain help decision-making. The questionnaire designed by scientific ad hoc committee divided into...
Primary immune thrombocytopenia (ITP) is a complex autoimmune disease whose hallmark deregulation of cellular and humoral immunity leading to an increased destruction reduced production platelets. The heterogeneity presentation clinical course hampers personalized approaches for diagnosis management. In 2021, the Spanish ITP Group (GEPTI) Society Hematology Hemotherapy (SEHH) updated consensus document which had been launched in 2011. guidelines have reference management primary Spain ever...
Abstract Faggot cells are an uncommon finding in nonacute promyelocytic leukemia, even rarer when observed mature granulocytic cells. Inv(16) should be dismissed pre‐eosinophilic granulation and faggot neutrophils observed.
Abstract Background Subcutaneous (SC) versus intravenous (IV) administration is advantageous in terms of patient convenience and hospital efficiency. This study aimed to compare the effect optimizing processes involved SC IV rituximab trastuzumab on capacity service quality. Methods cross-sectional resource utilization interviewed oncologists, hematologists, nurses, pharmacists from 10 hospitals Spain estimate changes associated with conversion trastuzumab, based clinical experience...
A 44-year-old woman presented with fever and arthralgia.Her past medical history included ulcerative colitis, which was treated azathioprine infliximab.On admission, a full blood count revealed hemoglobin level of 13 g/L, leukocyte 1.4x10 9 /L, platelets 108x10 /L.Peripheral smear showed 14% blast cells.The bone marrow hypocellular 79% large cells rounded nuclear contours, fine chromatin one to three nucleoli, basophilic cytoplasm, were compatible monoblasts.Erythrophagocytosis frequently...